FDA Grants Accelerated Approval for Imdelltra for the Treatment of Extensive-Stage Small Cell Lung Cancer
The FDA has approved Imdelltra™ (tarlatamab-dlle), manufactured by Amgen, for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
- Imdelltra is the first and only DLL3-targeting Bispecific T-cell Engager therapy that activates the
patient’s own T cells to attack DLL3-expressing tumor cells. - Imdelltra is administered as an intravenous infusion over one hour in an appropriate hospital
setting.
Source: Amgen
